RxDoctor Payments Data

Cyril Bethala, MD

Interventional Cardiology · Slidell, LANPI 1528178415

Payments from drug & device makers

$3,288in general payments, 2019–2025

Across 145 payments — averaging $22.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$707
  • Johnson & Johnson$367
  • Edwards Lifesciences$358
  • Boston Scientific$300
  • Pfizer$228
  • Irhythm Technologies, Inc.$160
  • plus $1K from 20 others

What the payments were for

  • Food & beverage$3,276100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,288 in reported general payments places this provider in the 15th percentile of 171 interventional cardiology providers in Louisiana.

See all interventional cardiology providers in Louisiana

Medicare billing

Part B allowed, 2024
$141,469
Medicare patients
1,182
Services billed
2,753

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban200$238,553
XareltoRivaroxaban47$54,979
EntrestoSacubitril/Valsartan30$42,487
Metoprolol Succinate169$2,808
ClopidogrelClopidogrel Bisulfate196$1,978
Potassium Chloride129$1,870
Atorvastatin Calcium161$1,381
Nebivolol Hcl37$1,256
Isosorbide Mononitrate ErIsosorbide Mononitrate110$1,255
Midodrine Hcl12$1,187
Pravastatin Sodium53$914
Amlodipine Besylate192$860
SotalolSotalol Hcl37$841
Rosuvastatin Calcium93$757
Torsemide87$695

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$228$238,553200 claims
Johnson & JohnsonXarelto$367$54,97947 claims
NovartisEntresto$126$42,48730 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 171 interventional cardiology providers in Louisiana.

Other interventional cardiology in Slidell

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →